Movement Alert｜Novo-Nordisk A/S Rises 3.01% in Regular Trading, JPMorgan Raises Target Price to 275 DKK

Market Focus08-25 23:19

On August 25, Novo-Nordisk A/S rose 3.01% in regular trading, trading at $48.3/share with turnover of $333 million. The move came as JPMorgan raised its target price on the company to 275 Danish kroner while maintaining a Neutral rating.

The upward revision follows the company's solid first-half financial performance. Total revenue reached 175.3 billion DKK (approximately $27.38 billion), representing a 13% year-over-year increase on a constant-currency basis, with semaglutide products serving as the primary revenue pillar. Net profit attributable to shareholders climbed 25.22% to 69.5 billion DKK ($10.86 billion). The company also recently initiated the OASIS 5 clinical trial evaluating lower doses of oral semaglutide for weight management in 450 participants, targeting completion by April 2028, as it seeks to expand its addressable patient population with more personalized dosing options.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment